UNSPSC 51273944: Lidocaine/sodium chloride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273944 Lidocaine/sodium chloride is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and medical supplies distributed through state health agencies, county health departments, and multistate cooperative purchasing consortia. The code sees active solicitation for generic pharmaceuticals, naloxone products, and over-the-counter medications supplied to support public health initiatives, emergency response programs, and state employee and benefit programs. Issuing bodies include state health and human services departments, county health systems, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The work spans product sourcing, compliance with federal manufacturing and supply-chain standards (cGMP, DSCSA, FDA requirements), and logistics coordination with authorized pharmaceutical wholesalers.

Recent activity clusters in Texas, Minnesota, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP on January 20, 2026 (due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with award effective July 1, 2026 and pricing weighted at 75 percent of evaluation criteria. Seminole County, Florida released an IFB on June 30, 2026 (due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, including shipping and delivery in vendor pricing. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capacity for self-insured health plans and state agencies, signaling future formal procurement downstream. Vendors must maintain compliance with drug supply chain security, Good Manufacturing Practices, insurance requirements (including commercial general liability up to $5 million per occurrence in multistate arrangements), and E-Verify employment verification.